Tumor-Targeted CD40 Antibody Shows Safe Profile but Limited Tumor Shrinkage in Phase 1 Trial
RO7300490, a FAP-targeted CD40 agonist, proved manageable in 80 advanced cancer patients but produced no objective tumor responses despite clear immune activation.
Summary
A first-in-human phase 1 trial tested RO7300490, a bispecific antibody designed to activate the immune system directly inside tumors by targeting fibroblast activation protein (FAP) while stimulating CD40 on dendritic cells. Eighty patients with advanced solid tumors received the drug at escalating doses. Side effects were mostly mild, with serious adverse events in fewer than 4% of patients and no deaths from treatment. The drug reached tumors effectively and triggered measurable immune changes — including increased dendritic cell activity and early formation of immune structures called tertiary lymphoid structures. However, no patients experienced tumor shrinkage, and only 42.5% achieved disease stabilization. The findings confirm the approach is safe and biologically active, but combination strategies will likely be needed to convert immune activation into meaningful clinical responses.
Detailed Summary
Activating the immune system within the tumor microenvironment is a central goal of modern cancer immunotherapy. CD40, a receptor on dendritic cells, plays a key role in priming tumor-killing T cells when activated. RO7300490 was engineered to deliver CD40 stimulation specifically to tumors by simultaneously binding fibroblast activation protein (FAP), a protein highly expressed in the tumor stroma. This targeting strategy was designed to concentrate immune activation at the tumor site while minimizing systemic toxicity — a longstanding challenge with earlier CD40 agonists.
This multicenter, single-arm phase 1 trial enrolled 80 patients with advanced or metastatic solid tumors across a wide dose range (16–1,100 mg), administered biweekly. The primary goal was to assess safety and tolerability, with secondary objectives covering pharmacokinetics, pharmacodynamics, and antitumor activity.
On the safety front, results were encouraging. Treatment-related adverse events occurred in 66% of patients, but the vast majority were grade 1 or 2. Serious grade 3–4 events were seen in only 3.8% of patients, discontinuations due to toxicity in 2.5%, and there were no treatment-related deaths. The drug demonstrated target-mediated drug disposition, with sustained exposure at higher doses confirming on-target engagement.
Despite clear tumor uptake confirmed by radiolabeled imaging and measurable intratumoral immune changes — including increased dendritic cell density and early tertiary lymphoid structure formation — no objective tumor responses were observed. Disease control (stable disease or better) was achieved in 42.5% of patients.
The disconnect between biological activity and clinical response suggests that CD40 agonism alone may be insufficient to overcome immune suppression in heavily pretreated advanced cancers. Combination with checkpoint inhibitors or other immunotherapies may be required to translate this immune priming into durable responses. The safety profile supports further development in combination regimens.
Key Findings
- No treatment-related deaths; grade 3–4 adverse events occurred in only 3.8% of 80 patients.
- Zero objective tumor responses observed despite confirmed tumor uptake of the drug.
- Disease control rate of 42.5% suggests biological activity without meaningful tumor shrinkage.
- Intratumoral dendritic cell density significantly increased, confirming immune activation in the tumor.
- Early tertiary lymphoid structures formed in tumors, a marker associated with better immunotherapy outcomes.
Methodology
Single-arm, multicenter, first-in-human phase 1 trial enrolling 80 patients with advanced or metastatic solid tumors across 10 dose levels (16–1,100 mg) administered biweekly. Primary endpoint was safety and tolerability; secondary and exploratory endpoints included pharmacokinetics, antitumor activity, and paired tumor biopsy pharmacodynamics. Radiolabeled drug imaging was used to confirm tumor uptake.
Study Limitations
Summary is based on the abstract only, as the full text is not open access; detailed subgroup analyses, dose-response relationships, and tumor-type-specific outcomes are unavailable. The trial was single-arm with no comparator, limiting interpretation of the disease control rate. The heavily pretreated, heterogeneous patient population may underestimate potential activity in earlier-line or selected tumor types.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.